In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China

References

• Luepke K, Mohr J. The antibiotic pipeline: reviving research and development and speeding drugs to market. Expert Rev Anti Infect Ther. 2017;15(5):425–433. doi:10.1080/14787210.2017.130825128306360
   PubMed Web of Science ®Google Scholar
• Falagas M, Mavroudis A, Vardakas K. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect? Expert Rev Anti Infect Ther. 2016;14(8):747–763. doi:10.1080/14787210.2016.120491127400643
   PubMed Web of Science ®Google Scholar
• Meng X, Liu S, Duan J, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. BMC Infect Dis. 2017;17(1):82. doi:10.1186/s12879-016-2176-928095785
   PubMed Web of Science ®Google Scholar
• Schwaber M, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. J Am Med Assoc. 2008;300(24):2911–2913.
   PubMed Web of Science ®Google Scholar
• Sheu C, Chang Y, Lin S, et al. EnterobacteriaceaeInfections caused by carbapenem-resistant: an update on therapeutic options. Front Microbiol. 2019;10:80. doi:10.3389/fmicb.2019.0008030761114
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69:S565–S575. doi:10.1093/cid/ciz83031724043
   PubMed Web of Science ®Google Scholar
• Burgos R, Biagi M, Rodvold K, et al. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection. Expert Opin Drug Metab Toxicol. 2018;14(10):1007–1021. doi:10.1080/17425255.2018.151170230106599
   PubMed Web of Science ®Google Scholar
• Gibson B, Brief A. Review of a new antibiotic: meropenem-vaborbactam. Sr Care Pharm. 2019;34(3):187–191.31155025
   PubMedGoogle Scholar
• Hackel M, Lomovskaya O, Dudley M, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1). doi:10.1128/AAC.01904-17
   Web of Science ®Google Scholar
• Dafopoulou K, Xavier B, Zarkotou O, et al. Detection of colistin resistance in the highly virulent Escherichia coli ST131 H30Rx clone in Greece. J Glob Antimicrob Resist. 2020;20:31–32. doi:10.1016/j.jgar.2019.11.01431786358
   PubMed Web of Science ®Google Scholar
• Johnson J, Johnston B, Kuskowski M, et al. Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 compared with other fluoroquinolone-resistant E. coli. Antimicrob Agents Chemother. 2015;59(8):4471–4480. doi:10.1128/AAC.00673-1525987621
   PubMed Web of Science ®Google Scholar
• Johnson J, Porter S, Thuras P, et al. Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2015;59(11):7132–7135. doi:10.1128/AAC.01687-1526324269
   PubMed Web of Science ®Google Scholar
• Tian X, Zheng X, Sun Y, et al. Escherichia molecular mechanisms and epidemiology of carbapenem-resistant isolated from Chinese patients during 2002–2017. Infect Drug Resist. 2020;13:501–512. doi:10.2147/IDR.S23201032110061
   PubMed Web of Science ®Google Scholar
• Castanheira M, Huband M, Mendes R, et al. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected Worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9). doi:10.1128/AAC.00567-17
   Web of Science ®Google Scholar
• Johnston B, Thuras P, Porter S, et al. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. J Glob Antimicrob Resist. 2021;24:190–197. doi:10.1016/j.jgar.2020.12.01733460842
   PubMed Web of Science ®Google Scholar
• Jorgensen S, Rybak M. Meropenem and vaborbactam: stepping up the battle against carbapenem-resistant Enterobacteriaceae. Pharmacotherapy. 2018;38(4):444–461. doi:10.1002/phar.209229427523
   PubMed Web of Science ®Google Scholar
• Zhou M, Yang Q, Lomovskaya O, et al. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China. J Antimicrob Chemother. 2018;73(10):2789–2796. doi:10.1093/jac/dky25129982437
   PubMed Web of Science ®Google Scholar
• Hecker S, Reddy K, Totrov M, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682–3692. doi:10.1021/acs.jmedchem.5b0012725782055
   PubMed Web of Science ®Google Scholar
• Wozniak A, Villagra N, Undabarrena A, et al. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. J Med Microbiol. 2012;61:1270–1279. doi:10.1099/jmm.0.045799-022700549
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/AAC.01443-17
   Web of Science ®Google Scholar
• Pfaller M, Huband M, Mendes R, et al. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Int J Antimicrob Agents. 2018;52(2):144–150. doi:10.1016/j.ijantimicag.2018.02.02129510189
   PubMed Web of Science ®Google Scholar
• Johnson J, Porter S, Thuras P, et al. Epidemic emergence in the United States of Escherichia coli sequence type 131-30 (ST131-30), 2000 to 2009. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.00732-17
   Web of Science ®Google Scholar